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Recently, adenosine has been proposed to be a bmetabolicQ switch that may sense and direct immune and inflammatory responses.
Inflammation and pro-inflammatory cytokine production are important in development of HIV-1 associated dementia, a devastating
consequence of HIV-1 infection of the CNS. The HIV-1 protein Tat induces cell death in the CNS and activates local inflammatory responses
partially by inducing calcium release from the endoplasmic reticulum. Because activation of adenosine receptors decreases production of the
pro-inflammatory cytokine TNF-a in several experimental paradigms both in vitro and in vivo, we hypothesized that adenosine receptor
activation would control both increased intracellular calcium and TNF-a production induced by Tat. Treatment of primary monocytes with
Tat significantly increased the levels of intracellular calcium released from IP3 stores. Activation of adenosine receptors with CGS 21680
inhibited Tat-induced increases of intracellular calcium by 90 F 8% and was dependent on protein phosphatase activity because okadaic acid
blocked the actions of CGS 21680. Tat-induced TNF-a production was inhibited 90 F 6% by CGS 21680 and concurrent treatment with
okadaic acid blocked the inhibitory actions of CGS 21680. Using a model monocytic cell line, CGS 21680 treatment increased cytosolic
serine/threonine phosphatase. Together, these data indicate that A2A receptor activation increases protein phosphatase activity, which blocks
IP3 receptor-regulated calcium release and reduction of intracellular calcium inhibits TNF-a production in monocytes.
D 2004 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.(HAD) is an important manifestation of HIV infection (Nath
and Berger, 2004) which include clinical symptoms of
ataxia, memory loss, and cognitive, motor and behavioral
abnormalities. Before the development of highly active anti-
retroviral therapy (HAART), incidence of HIV dementia
was 20% in HIV-1-infected individuals (Manji and Miller,
2004). While HAART therapy has lowered the number of
patients who develop HAD by 50% (Manji and Miller,
2004), HAD remains an important neurological complica-
tion of HIV infection. Pathologically, HAD is associated
with astrogliosis, neuronal loss, demyelination, and inflam-
mation (Rappaport et al., 1999; Wiley et al., 1998).
Development and progression of HAD is thought to
associate with infiltration of peripheral immune cells into04) 186–195
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viral infection results in secondary events causing patho-
logy. Central to these secondary events may be the HIV-1
protein Tat. Tat is produced by HIV-infected cells and assists
in viral replication by binding to a transactivation response
element in HIV-1 mRNAs and promoting transcriptional
initiation and elongation (Rappaport et al., 1999; Saha and
Pahan, 2003). Tat can also bind to and activate transcription
of host genes whose products may be involved in develop-
ment of HAD. Tat binds to the genes encoding collagen and
fibronectin, two extracellular matrix proteins involved in
cell adhesion (Rappaport et al., 1999). Tat also binds to the
gene encoding the pro-inflammatory cytokine TNF-a and
activates its transcription (Rappaport et al., 1999). TNF-a is
postulated to play a central role in HAD development by
damaging astrocytes function and potentially reducing their
neuroprotective actions (Jones et al., 1998; Nath et al., 1996,
1998; Saha and Pahan, 2003). TNF-a expression is
increased in macrophages isolated from HIV-1 patients
and Tat injected in the brains of mice increases TNF-a in
cerebrospinal fluid (CSF) and increases monocyte/macro-
phage infiltration into the central nervous system (CNS)
(Jones et al., 1998; Philippon et al., 1994; Pu et al., 2003;
Rappaport et al., 1999; Saha and Pahan, 2003).
Infiltration of monocytes into the CNS is an early feature
of HIV-1 infection and later recruitment of macrophages
may be a key step in CNS disease development. Tat is
produced and released by infected macrophages and micro-
glia and can then interact with uninfected macrophages
(Rappaport et al., 1999). Macrophages respond by produ-
cing inflammatory mediators including TNF-a. TNF-a may
contribute to HAD by directly inducing neurotoxicity, by
synergizing with other viral toxins (gp120) or excitotoxins
(glutamate) (Saha and Pahan, 2003), and by increasing
leukocyte migration across the blood–brain barrier by
increasing chemokine production and adhesion molecule
expression on endothelial cells (Nottet et al., 1997; Pu et al.,
2003; Rappaport et al., 1999). Tat also induces toxicity
within the CNS by causing Ca2+ dysregulation, excitoto-
xicity, and altering cytokine production (Benjouad et al.,
1993; Chen et al., 1997; Cheng et al., 1998; Haughey et al.,
1999; Johnston et al., 2001; Jones et al., 1998; Rappaport et
al., 1999). Because Tat appears to promote an inflammatory
response within the CNS that contributes to HAD pathol-
ogy, understanding endogenous immune modulators will
give us insight into mechanisms of disease progression and
may identify novel targets for drug intervention.
One such immune modulator is the purine nucleoside
adenosine. Adenosine can influence the function of mono-
cytes, macrophages, neutrophils, T cells, and dendritic cells
suggesting that adenosine may play a key role in regulating
inflammation and immune responses (Bouma et al., 1994;
Bowlin et al., 1997; Cronstein, 1994; Eigler et al., 1997;
Hasko et al., 1996, 2000; Link et al., 2000;Mayne et al., 2001;
McWhinney et al., 1996; Ohta and Sitkovsky, 2001; Revan et
al., 1996; Sajjadi et al., 1996; Sitkovsky, 2003). Morespecifically, numerous studies have identified the ability of
adenosine and adenosine receptor agonists to control cytokine
production. Adenosine controls TNF-a in monocytes and
macrophages activated by several inflammatory stimuli and
may also control TNF-a production induced by Tat. As a
result, we designed experiments to identify signaling mech-
anisms involved in adenosine-mediated inhibition of Ca2+
and TNF-a production as indicators of the potential protective
and anti-inflammatory properties of adenosine.Results
Adenosine inhibits Tat-induced increases of [Ca2+]i
As previously reported for primary cultures of human
neurons, astrocytes (Haughey et al., 1999) and macrophages
(Mayne et al., 2000), Tat induced a transient and statistically
significant increase of [Ca2+]i in primary human monocytes
(Fig. 1a). Tat-induced increases of [Ca2+]i appeared to
originate from intracellular stores because the increases
were similar when Tat was applied in the absence or
presence of extracellular calcium (Fig. 1b). Xestospongin C,
an inhibitor of IP3 receptor-dependant calcium release,
significantly (P b 0.001) reduced ATP-induced (data not
shown) and Tat-induced initial calcium transients from
742 F 44 to 42 F 9 nM (Fig. 1d) indicating that the source
of intracellular calcium was IP3 receptor-regulated stores in
the endoplasmic reticulum. Confirming previous observa-
tions (Mayne et al., 2000), the increases of [Ca2+]i by Tat
were not significantly affected by pre-treatment with 10 AM
ryanodine (data not shown) indicating that increases in
[Ca2+]i are not from ryanodine receptor-regulated stores.
Adenosine receptor activation inhibited calciummobilization
from IP3 receptor-regulated stores induced by Tat and ATP
Addition of the adenosine receptor agonist CGS 21680
(100 nM) blocked Tat-induced increases of [Ca2+]i (Fig. 1a)
and significantly inhibited ATP-induced increases of [Ca2+]i
(Fig. 1c). Inhibition of Tat-induced increases of [Ca2+]i by
CGS 21680 were completely blocked by the adenosine A2A
receptor antagonist ZM 241385 suggesting that these effects
were mediated by adenosine A2A receptors (Fig. 1b).
Endogenous adenosine regulated Tat-induced increases of
[Ca2+]i because both ZM 241385 and adenosine deaminase
significantly increased [Ca2+]i (Fig. 1d). ZM 241385
blocked the actions of endogenous adenosine on A2A
receptors and adenosine deaminase increased endogenous
adenosine levels by inhibiting adenosine metabolism.
Signal transduction systems involved in CGS 21680
regulation of Tat-induced increases of [Ca2+]i
We next determined signaling events downstream of
A2A receptor activation responsible for the above observed
Fig. 1. Activation of A2A adenosine receptors inhibits calcium release from IP3 receptor-regulated stores in monocytes. (a) Tat-induced increases of [Ca
2+]i
were blocked by CGS 21680. (b) Independent of the presence (dark bars) or absence (white bars) of extracellular calcium, CGS 21680 (100 nM) significantly
decreased Tat-induced increases of [Ca2+]i, and the actions of CGS 21680 were blocked by the adenosine A2A receptor antagonist ZM 241385 (10 nM). The
removal of extracellular calcium did not alter intracellular calcium levels when cells were treated with the A2A agonist and/or antagonist alone (not shown). (c)
CGS 21680 decreased significantly ATP-induced increases of [Ca2+]i. (d) Tat-induced increases of [Ca
2+]i originated from IP3 receptor-regulated pools because
xestospongin C (1 AM) blocked Tat-induced increases of [Ca2+]i irrespective of the absence or presence of extracellular calcium. Blocking A2A receptors with
ZM 241385 (10 nM) or decreasing adenosine levels using adenosine deaminase (2 IU/ml) before Tat treatment significantly increased [Ca2+]i. Levels shown are
mean F SEM values from experiments conducted using monocytes purified from six individuals. Arrows indicate additions of Tat or ATP. ***P b 0.001 vs.
Tat and **P b 0.01 vs. Tat.
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phospholipase C with 1 AM U71322 or type 1 protein
kinase C with 1 AM H7 attenuated significantly Tat-
induced increases in TNF-a production by approximately
90% in primary macrophages (Mayne et al., 2000).
Because A2A receptors activate, through Gs protein linked
processes, an increase in cAMP levels and PKA activity
(Olah and Stiles, 1995), we hypothesized that these
signaling pathways were involved in A2A receptor-media-
ted inhibition of Tat-induced increases of [Ca2+]i origina-
ting from IP3-regulated stores. However, decreases in Tat-
induced increases of [Ca2+]i by CGS 21680 were not
reversed by 1 AM SQ 22536, an inhibitor of adenylyl
cyclase or 1 AM H89, a selective inhibitor of PKA (Fig.
2). Because A2A receptors have been linked to activation
of protein phosphatases (Revan et al., 1996), we deter-
mined whether an inhibitor of serine/threonine protein
phosphatase, okadaic acid, would reverse the actions of
CGS 21680. Okadaic acid did not inhibit Tat-induced
increases of [Ca2+]i, but did reverse the actions of CGS21680 on Tat-induced increases of [Ca2+]i (Fig. 2)
indicating that the effect of CGS 21680 on [Ca2+]i was
mediating by serine/threonine protein phosphatase.
CGS 21680 inhibits Tat-induced TNF-a production through
serine/threonine protein phosphatase
Previously, we reported that Tat induces the release of
calcium from IP3 receptor-regulated pools of intracellular
calcium and that this calcium partially regulates Tat-
induced TNF-a production (Mayne et al., 2000). Because
CGS 21680-mediated inhibition of [Ca2+]i required protein
phosphatase, we tested the hypothesis that the inhibitory
actions of CGS 21680 on TNF-a production were
similarly regulated by protein phosphatase activation. As
expected, TNF-a production was significantly inhibited by
CGS 21680 when added 30 min before the addition of Tat
(100 nM) or LPS (100 nM) (Figs. 3a and b). The anti-
TNF-a effects of CGS 21680 were mediated by A2A
receptors because the A2A receptor antagonist ZM 214385
Fig. 2. A2A receptor activation blocked Tat-induced increases of [Ca
2+]i by mechanism(s) dependent on protein phosphatase activation and independent of
cAMP and PKA. A2A receptor activation with CGS 21680 decreased Tat-induced increases of [Ca
2+]i, and the effects of CGS 21680 were reversed by okadaic
acid (100 nM) but not by SQ 22536 (1 AM) or H89 (1 AM). Okadaic acid (1 or 10 nM) did not reverse the actions of CGS 21680 (not shown). Levels shown are
mean F SEM values from experiments conducted using monocytes purified from six individuals. **P b 0.001.
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and b). Okadaic acid (100 nM) reversed the inhibitory
actions of CGS 21680 against Tat- and LPS-induced
increases of TNF-a production (Figs. 3a and b) indicating
that the anti-TNF-a effects of CGS 21680 required protein
phosphatase.
CGS 21680 increases cytosolic serine/threonine
phosphatase activity
Because okadaic acid, a serine/threonine phosphatase
inhibitor, reversed the anti-TNF-a effects of CGS 21680, we
hypothesized that adenosine receptor activation by CGS
21680 increases phosphatase activity. We measured phos-
phatase activity in cytosolic and membrane protein extracts
of pro-monocytic U937 cells as a model of monocytes
because our enzyme assay required cell numbers that
could not be obtained from primary monocyte cultures.
To verify that U937 cells would provide a model similar
to human monocytes with respect to signaling pathways
activated by CGS 21680, we measured TNF-a production
in these cells induced by phorbol esters in the presence
and absence of CGS 21680 (Fig. 4a). The anti-TNF-a
effects of CGS 21680 and the requirement of protein
phosphatase was similar in U937 cells and primary hu-
man monocytes (Figs. 3 and 4a). CGS 21680 increased
serine/threonine phosphatase activity in cytosolic extracts
after 10 min. These increases in enzyme activity
decreased to basal levels after 60 min (Fig. 4b). In
membrane preparations, we found no significant increases
in enzyme activity up to 60 min following CGS 21680
administration.Discussion
Inflammation is a central feature in the early stages of
HIV-1 infection of the CNS and may be involved in later
stages of CNS disease development. Stimulatory actions of
the HIV-1 protein Tat on macrophages and monocytes
infiltrating into the CNS during infection may contribute to
inflammation and tissue damage associated with HAD. Tat
is thought to cause dysfunction and death of neural cells by
inducing dysregulation of cytokines and chemokines pro-
duced by infiltrating immune cells within the brain
(Rappaport et al., 1999). Tat itself also induces neuronal
death by facilitating the excitotoxic actions of glutamate
(Haughey et al., 2001; Self et al., 2004). Understanding
endogenous mechanisms for controlling neuroinflammation
is essential for designing therapies that can target the
inflammatory and toxic actions of Tat.
The purine nucleoside adenosine was recently proposed
to act as a bmetabolic switchQ capable of sensing different
degrees of inflammation and subsequently triggering an
appropriate immune response (Sitkovsky, 2003). This
proposal was based on findings that adenosine levels are
increased during inflammatory responses in a manner that
reflects severity of inflammation. Although adenosine is a
well-studied molecule, signaling mechanisms governing its
anti-inflammatory actions are not well understood. As an
endogenous immune regulator, adenosine may play an
important role therapeutically for CNS inflammatory dis-
orders and its signaling mechanisms become important as
novel therapeutic targets.
Consistent with other studies, we found that activation of
adenosine A2A receptors significantly inhibited TNF-a
Fig. 3. Adenosine A2A receptor activation inhibits TNF-a production in monocytes treated with pro-inflammatory agents Tat or LPS in a protein phosphatase
dependent manner. CGS 21680 (C) significantly decreased the production of TNF-a stimulated by Tat (a) or LPS (b) and the adenosine A2A receptor antagonist
ZM 241385 (Z) reversed these effects. The serine/threonine protein phosphatase inhibitor okadaic acid (OA; 100 nM) alone did not affect levels of TNF-a
production, but reversed the inhibitory actions of CGS 21680 on TNF-a production. The anti-TNF-a effects of CGS 21680 were unchanged by the tyrosine
phosphatase inhibitor dephostatin (D; 1 AM). TNF- a levels shown are mean F SEM values from experiments conducted using monocytes purified from six
individuals. ***P b 0.001 vs. Tat or LPS, +P b 0.001 vs. CGS+Tat or CGS+LPS.
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Sitkovsky, 2003). Because TNF-a may play a pathological
role in HAD, this finding suggests that pharmacological
manipulations of adenosine systems may be an effective
therapeutic strategy against HIV-1 encephalopathy. In
addition, endogenous adenosine appears to be involved in
regulating TNF-a production and intracellular calcium
because the A2A receptor antagonist ZM 241385 alone
elevated levels of TNF-a and intracellular calcium (Figs. 1
and 3).
Here, we report that the inhibitory actions of adenosine
receptor activation on Tat-induced release of calcium fromIP3 receptor-regulated stores and on Tat-induced TNF-a
production were dependent on protein phosphatase. Impor-
tantly, decreases in intracellular calcium by CGS 21680 did
not involve activation of adenylyl cyclase and PKA. This
finding suggests that the signaling mechanisms governing
control of calcium levels are independent of classical A2A
receptor pathways (Collis and Hourani, 1993; Fredholm et
al., 2001). Serine/threonine phosphatases may be an
important part of this novel signaling pathway and have
also been implicated in regulation of neutrophil function by
adenosine A2 receptors (Revan et al., 1996). By regulating
actions of adenosine in neutrophils and monocytes, protein
Fig. 4. Adenosine A2A receptor activation increases cytosolic serine/threonine phosphatase activity. (a) U937 cells were stimulated with PMA/PHA for 4 h
alone or in combination with CGS 21680, okadaic acid to inhibit serine/threonine phosphatase, dephostatin to inhibit tyrosine phosphatase, or sodium
orthovanadate to inhibit tyrosine phosphatase. The anti-TNF-a effects of CGS 21680 were reversed by okadaic acid. (b) Serine/threonine phosphatase activity
was measured in cytosolic and membrane extracts from U937 cells treated with CGS 21680 for time intervals ranging from 5 to 60 min. **P b 0.01 vs. time 0,
***P b 0.001 vs. untx, +P b 0.001 vs. PMA/PHA + CGS.
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of adenosine. Protein phosphatases regulate cellular signal-
ing events and direct diverse and broad cellular functions
including neurotransmission, muscle contraction, glycogen
synthesis, T cell activation, cellular plasticity, and diffe-
rentiation (Aggen et al., 2000). Eukaryotic cells contain
tyrosine and serine/threonine phosphatase activity (Hunter,
1995), and within the serine/threonine category, there are at
least eight major types (Aggen et al., 2000). Of these, four
major isoforms have been studied in detail including PP1,
PP2A, PP2B (calcineurin), and PP2C. Because our studies
used okadaic acid, findings here implicate a role for PP1
and/or PP2A. Doses of okadaic acid used in our studies (nM
range) suggested that okadaic acid is acting primarily on
PP1 because PP1 is blocked by only high nM concentrations
of okadaic acid (Cohen et al., 1989) and we did not observe
inhibition of the anti-TNF-a effects of CGS 21680 with
okadaic acid at 1 nM concentration (data not shown).
Blocking protein phosphatase activation can reverse
several signal transduction events including the release of
calcium from IP3 receptor-regulated stores (Hu et al., 1997;Jimenez et al., 1999). The cellular targets of protein
phosphatase may include protein kinase C and PLC, both
of which are critical for Tat-induced TNF-a production and
are regulated by intracellular calcium (Kirk and Richardson,
1995; Liang and Morley, 1996; Norenberg et al., 1997, 1998;
Sexl et al., 1997). Protein phosphatase may also dephos-
phorylate IP3 receptors and block their activation (Jayaraman
et al., 1996). Our previous results showing that blocking
PKC activation reduces both calcium release from IP3
receptor-regulated pools and TNF-a production is consistent
with this latter mechanism of action (Mayne et al., 2000).
Although our previous findings indicated that intra-
cellular calcium release from IP3R-regulated stores is
involved in TNF-a production (Mayne et al., 2000),
findings reported here do not prove that A2A mediated
inhibition of TNF-a production is solely dependent on
release of calcium from IP3 receptor-regulated stores.
Rather, our data indicate that A2A activation and inhibition
of TNF-a is dependent on protein phosphatase activity and
in part, reduction of high levels of intracellular calcium. The
latter statement is supported by our previous observation
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xestospongin C (an inhibitor of IP3 receptors) in macro-
phages reduced TNF-a production by approximately 30%
(Mayne et al., 2000).
Based on these observations, we have proposed an
adenosine A2A receptor signaling pathway outlined in Fig.
5. Tat stimulation of human monocytes increases intra-
cellular calcium levels by inducing calcium release from
endoplasmic reticulum pools. Increased intracellular calcium
induces TNF-a transcription and protein production by
activating calcium-dependent signaling pathways including
PKC and NF-nB. By activating serine/threonine protein
phosphatase activity, adenosine receptor activation effi-
ciently controls intracellular calcium levels and TNF-a
production induced by the HIV-1 protein Tat. Protein
phosphatase may control calcium release by decreasing
phosphorylation of endoplasmic reticulum IP3. By control-
ling intracellular calcium, adenosine receptors may control
TNF-a production at a pre-transcriptional level. In a human
monocyte cell line stimulated with phorbol esters, adenosine
receptor activation controlled TNF-a production post-tran-
scriptionally by decreasing mRNA stability (Fotheringham
et al., 2004, revised manuscript submitted). Adenosine
receptors may then control TNF-a induced by Tat pre-
transcriptionally through intracellular calcium and post-
transcriptionally through mRNA stability. Activating cell
signaling pathways that can control cytokine production both
pre- and post-transcriptionally may allow adenosine recep-
tors to efficiently control cytokine production in monocytes
and macrophages induced by multiple stimuli. Clearly, TNF-Fig. 5. Schematic of proposed signaling mechanisms mediating the anti-
inflammatory actions of adenosine receptors. The HIV-1 protein Tat induces
TNF-a production in monocytes in part by increasing release of calcium
from IP3-receptor-regulated stores in the ER. Activation of adenosine
receptors increases cytosolic PP1 activity that can control both calcium
release and TNF-a production. PP1 may control TNF-a production by
blocking calcium release and by controlling Ca2+-dependent signaling such
as transcription factor activation. Because phosphorylation of IP3 receptors
increases calcium release, PP1 may control calcium by decreasing receptor
phosphorylation. Finally, by controlling both Ca2+ and cytokine production,
adenosine receptor activation may have significant effects of cellular
signaling, particularly pathways dependent on Ca2+-like calcineurin.a protein production and regulation involves complex
signaling events in monocytes and macrophages and the
consistent regulation of TNF-a by A2A receptor activation
implicates adenosine as an important endogenous regulator
of pro-inflammatory cytokine production.Materials and methods
Chemicals and recombinant Tat1–72
Fura-2-acetoxymethyl ester (Fura-2/AM) was obtained
from Molecular Probes Inc. (Eugene, OR). EGTA, L-leucine
methyl ester and neomycin were purchased from Sigma (St.
Louis, MO). Xestospongin C and okadaic acid were
purchased from Calbiochem (San Diego, CA). All drugs
were dissolved in Krebs buffer except for ryanodine that
was dissolved in ethanol and diluted with Krebs (final
ethanol concentration was 0.05%). Tat1–72 was prepared and
purified as described previously (Ma and Nath, 1997) and
biological activity was confirmed by activation of h-
galactosidase in transfected HeLa cells (AIDS Repository,
NIH). Tat protein was lyophilized and stored at 80 8C until
taken for assay. The serine/threonine phosphatase assay kit
was purchased from New England Biolabs (Pickering, ON).
Primary monocyte culture preparation
Human peripheral blood mononuclear cells (PBMC)
were purified from whole blood obtained from healthy
volunteers as outlined previously (Mayne et al., 2000).
Briefly, peripheral blood monocytes were isolated from
whole blood from healthy donors using a Ficoll isolation
gradient. The white blood cell layer was plated on T75
flasks over night in RPMI medium containing 10% FBS and
1% antibiotics. Adherent monocytes were scraped and
cultured at a density of 2  105 cells/ml for 7 days in
RPMI supplemented with 10% FBS and antibiotics. All
cells were maintained at 37 8C in a humidified growth
chamber supplemented with 5% CO2.
U937 cell culture preparations
Human pro-monocytic U937 cells (ATCC CRL 1593.2;
batch F12641) were obtained from American Type Culture
Collection (Rockville, MD) and cultured in RPMI 1640 (pH
7.2) media supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 1% antibiotic/antimycotic (Chen et
al., 1997). Cells were maintained at 37 8C in a humidified
growth chamber supplemented with 5% CO2.
Levels of intracellular calcium
([Ca2+]i): [Ca
2+]i were determined using the Ca
2+-
specific fluorescent probe Fura-2/AM as described previ-
ously (Haughey et al., 1999; Mayne et al., 2000). Cover
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LU-CSD Leiden cover slip dish situated in a PDMI-2 open
perfusion micro-incubator (Medical Microsystems Corp.,
Greenvale, NY) and the cells were superfused at the rate of
2 ml/min with Krebs buffer pre-warmed to 37 8C. Cells
were excited at 340 and 380 nm, and emission was recorded
at 510 nm with a video-based Universal Imaging system
(EMPIX, Mississauga, ON). Rmax/Rmin ratios were con-
verted to nM [Ca2+]i (Grynkiewicz et al., 1985). All images
were acquired by real time averaging of 16 frames of each
wavelength that included a background reference subtrac-
tion from each of the acquired images. Tat (100 nM) was
loaded into glass micropipettes (1.0 mm OD, 0.78 mM ID)
pulled to a final outer tip diameter of b1.0 Am. Micro-
pipettes were positioned approximately 3 cell bodies away
from target cells and Tat was pressure-applied to cells (3 
100 ms, 8 psi) using a Picospritzer (General Valve Corp,
Fairfield, NJ). Peak increases of [Ca2+]i were determined by
calculating the difference between maximum [Ca2+]i levels
achieved during a 5-min period following Tat applications
and baseline [Ca2+]i.
Tat treatment of primary monocytes and TNF-a assays
Primary monocyte cultures (200,000 cells/ml) were
maintained in RPMI media supplemented with 10% FBS
and antibiotics for 7 days following purification. The cells
were subsequently stimulated for 4 h with 100 nM Tat. In
some experiments, cells were pretreated for 30 min with
pharmacological agents before addition of Tat. In experi-
ments where effects on TNF-a production were determined,
cells were incubated for 4 h at 37 8C following the addition
of Tat and supernatants were collected, centrifuged at 700 
g for 5 min and analyzed for TNF-a by ELISA (Mayne et
al., 2000). Positive controls were incubated for 4 h with 100
ng/ml lipopolysaccharide (LPS, Escherichia coli type
055:B5, Sigma). For all experiments, Tat was used
immediately following thawing and tubes and tips used
with Tat were siliconized.
U937 cells were cultured to a density of 800,000 cells/ml
in RPMI growth media and were plated in 96 well plates
with fresh media at a density of 800,000 cells/ml 1 h before
each experiment. TNF-a production was induced using 10
ng/ml phorbol-12-myristate-13-acetate (PMA) and 5 Ag/ml
phytohemagglutinin (PHA) for 4 h at 37 8C. PMA is a
phorbol ester that activates protein kinase C, a well-
characterized signaling pathway that transmits signals in
activated immune cells. PHA is a mitogen that stimulates
cell proliferation and agglutination, both consequences of
monocyte and lymphocyte activation. TNF-a levels were
determined by ELISA (Chen et al., 1997).
Serine/threonine phosphatase activity assays
Serine/threonine protein phosphatase activity was deter-
mined using a commercially available enzyme assay kit(New England Biolabs). Briefly, myelin basic protein
(MyBP) was labeled on serine and threonine residues
with [g-33P] ATP by protein kinase A. Experimental
protein extracts containing active protein phosphatases
were incubated with 33P labeled MyBP. Protein phospha-
tase activity was determined by measuring 33P released
from MyBP during incubation with experimental protein
extracts, indicating degree of dephosphorylation of labeled
MyBP. Experiments were performed on U937 cells
cultured to a density of 1000000 cells/ml in RPMI
1640 media supplemented with 10% FBS. Following
experimental treatments, cells were collected on ice and
pellets were washed once in ice-cold PBS. After washing,
cell pellets (approximately 10  106 cells/pellet) were
resuspended and homogenized. Whole cells, nuclei and
large debris were removed by centrifugation for 10 min at
300  g at 4 8C. Supernatant was collected and
centrifuged for 20 min at 18 000  g at 4 8C.
Supernatant was collected (cytosolic fraction) and pellets
(membrane fraction) were resuspended in 1 protein
phosphatase buffer (NEB kit). Protein content in both
fractions was determined by Bradford assay (BioRad
Laboratories). 100 ng of protein from membrane or
cytosol fractions were used to measure serine/threonine
phosphatase activity (New England Biolabs kit) as per
manufacturer’s instructions.
Statistical analysis
Significant differences between groups were determined
by one-way ANOVA with Tukey’s post hoc comparisons.
For all tests, statistical significance was considered to be at
P b 0.05 (Instat2, Graphpad Software, San Diego, CA).Acknowledgments
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